The foundation of CMS’s proprietary technology was instrumental in launching the first Oral Thin Film (OTF) containing an active drug ingredient. Following the successful launch of several OTC and nutraceutical products, CMS successfully launched the first OTF with cannabinoids in 2008. Since then, CMS has continued its research and development efforts and subsequently launched a diverse range of products featuring its patented drug delivery systems and encapsulation technologies.
Over the last few years, CMS has been able to transition the technology-based products into mass manufacturing and bring cGMP certified retail products into the rapidly growing cannabinoid market. CMS exceeds the industry standards by operating and adhering to pharmaceutical and FDA drug standards with trusted analytical data, consistent measured dosing, and responsible business practices.